Thymosin Alpha-1 Research: The 28-Residue Thymic Peptide and What Studies Have Examined

Thymosin alpha-1 explained for researchers: isolation from thymosin fraction 5, its 28-residue sequence, its prothymosin alpha origin, NMR structure and dendritic cell and TLR studies.

Share

Thymosin alpha-1, usually written Ta1, is one of the most studied peptides to come out of thymus research. It is short, strongly acidic, acetylated at its N-terminus and, despite the shared family name, unrelated in sequence to thymosin beta-4, the actin-binding peptide behind TB-500. This overview covers where Ta1 came from, what its structure looks like, how it relates to its larger precursor protein, and what the published mechanistic work has actually examined. It is written for laboratory researchers.

From thymosin fraction 5 to a single peptide

The story starts in the 1960s in the laboratory of Allan Goldstein and Abraham White. In 1966, Goldstein, Slater and White described, in the Proceedings of the National Academy of Sciences (PNAS), the preparation and partial purification of a thymic factor they called thymosin. Over the following decade the crude calf thymus extract was refined into a partially purified mixture known as thymosin fraction 5, which contained a family of small polypeptides.

The peptides in fraction 5 were named by their position on isoelectric focusing gels. The acidic ones were called alpha thymosins, the neutral ones beta, and the basic ones gamma. That naming convention is why thymosin alpha-1 and thymosin beta-4 share a family name but have nothing structural in common.

In 1977, Goldstein, Low, McAdoo and colleagues reported in PNAS the isolation and sequence analysis of thymosin alpha-1 itself. They described a 28-amino-acid polypeptide with an acetylated N-terminal serine and a molecular weight of about 3,100. A fuller account of the amino acid sequence analysis by Low and Goldstein followed in the Journal of Biological Chemistry in 1979.

The sequence and what it means for handling

The sequence of Ta1 is:

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

A few features stand out for anyone handling or analysing it:

  • It is strongly acidic. Glutamic and aspartic acid residues outnumber the lysines, so the peptide carries a net negative charge at neutral pH. This affects its retention on reversed-phase HPLC and its behaviour in ion-exchange methods.
  • The N-terminus is acetylated. That blocks the free amine, which matters for classical Edman sequencing (a blocked N-terminus cannot be read directly) and shifts the expected mass by 42 daltons compared with an unacetylated chain.
  • It contains no cysteine, methionine or tryptophan, so the oxidation pathways that trouble many research peptides are less of a concern. Asparagine at the C-terminus and several aspartate residues are still potential sites for deamidation and aspartimide-related degradation, which we cover in our guide to peptide degradation pathways.

Because the sequence is short, acidic and disulfide-free, Ta1 is a common solid-phase peptide synthesis target; the general chemistry is described in our article on solid-phase peptide synthesis.

A fragment of a much larger protein

One of the more interesting findings about Ta1 is that it is not an independently encoded gene product. In 1984, Haritos, Goodall and Horecker reported in PNAS that the major immunoreactive form of thymosin alpha-1 in rat thymus is actually the N-terminal portion of a much larger, highly acidic nuclear protein they named prothymosin alpha. In other words, the 28-residue peptide corresponds to the first stretch of prothymosin alpha, and much of the "thymosin alpha-1" measured in tissue is generated from that precursor.

This precursor relationship is important when interpreting older biochemistry. Measurements made with antibodies raised against the 28-mer may have been detecting the intact precursor, fragments of it, or the free peptide, depending on the assay. It is a good example of why the analytical method behind a reported concentration matters as much as the number itself.

Structure: disordered in water, helical in membrane-like conditions

A recurring theme in the structural literature is that Ta1 has little fixed structure in plain aqueous buffer. It behaves as an intrinsically disordered peptide in water, which is unsurprising for a short, highly charged chain.

That picture changes in membrane-mimicking or alcohol-containing environments. Elizondo-Riojas, Chamow, Tuthill, Gorenstein and Volk reported an 800 MHz NMR structure of the 28-residue peptide in a 40% trifluoroethanol / 60% water mixture in Biochemical and Biophysical Research Communications in 2011. Restrained molecular dynamics in an explicit TFE/water solvent box were used to generate the structure, which showed helical character that is not present in pure water. A later review by Volk, Tuthill, Elizondo-Riojas and Gorenstein in the Annals of the New York Academy of Sciences in 2012 summarised the NMR work on Ta1 and the beta-thymosins, noting that the helical structure appears in the presence of trifluoroethanol or lipid vesicles.

The practical reading of this is that Ta1 is a conformationally flexible peptide whose shape depends heavily on its environment, a property it shares with many short signalling peptides.

What mechanistic studies have examined

Most of the detailed mechanistic work on Ta1 concerns the immune system, and in particular how it interacts with cells of the innate immune response. A widely cited study by Romani and colleagues, published in Blood in 2004, examined thymosin alpha-1 and dendritic cells. Working in experimental models, the authors reported that Ta1 activated dendritic cells through Toll-like receptor signaling, specifically implicating TLR9 and the downstream adaptor MyD88, and that this activation shifted the response toward a Th1-type, antifungal pattern. This gave a concrete molecular entry point, a pattern-recognition receptor, for effects that had previously been described only at the level of whole-animal immunology.

Review articles have tried to pull the broad literature together. Goldstein and Goldstein, writing in Expert Opinion on Biological Therapy in 2009, surveyed the then-emerging applications and the proposed immunomodulatory mechanisms. Tuthill, Rios and McBeath summarised the clinical experience and open questions in the Annals of the New York Academy of Sciences in 2010. These reviews are useful orientation, but readers should treat them as secondary sources and go back to the primary mechanistic papers for the actual experimental detail.

It is worth being precise about what these studies are and are not. The mechanistic work describes receptor engagement and immune-cell signalling in laboratory and animal systems. None of it is a basis for claims about effects in people, and this article makes none.

Analytical notes for the bench

Several of the general analytical challenges we have covered elsewhere apply directly to Ta1:

  • Confirming identity. Because the N-terminus is acetylated, intact-mass measurement and tandem mass spectrometry (covered in our article on peptide sequencing by MS/MS) are the practical ways to confirm the sequence; classical N-terminal Edman sequencing will stall on the blocked terminus.
  • Purity. Reversed-phase HPLC is the workhorse for purity, but the strongly acidic sequence means method conditions matter; see our comparison of HPLC and mass spectrometry for peptide testing.
  • Net content. As with any lyophilised acidic peptide, the mass in the vial includes counter-ions and residual water, so HPLC purity and net peptide content are different numbers, a distinction we explain in our guides to peptide counter-ions and net content versus HPLC purity.
  • Deamidation. The C-terminal asparagine and the several aspartates are the residues to watch for deamidation and aspartimide formation on storage.

Summary

Thymosin alpha-1 is a 28-residue, N-terminally acetylated, strongly acidic peptide first sequenced in 1977 and later shown to be the N-terminal fragment of the larger protein prothymosin alpha. Structurally it is disordered in water and becomes helical in membrane-like or alcohol-containing conditions, as the 2011 NMR work showed. Mechanistically, the best-characterised published findings link it to dendritic cell activation through Toll-like receptor signalling. For the laboratory, its acetylated terminus, acidic sequence and asparagine/aspartate content shape how it is synthesised, confirmed and stored.

References

  • Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proceedings of the National Academy of Sciences. 1966;56(3):1010-1017. doi:10.1073/pnas.56.3.1010.
  • Goldstein AL, Low TLK, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences. 1977;74(2):725-729. doi:10.1073/pnas.74.2.725.
  • Low TLK, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. Journal of Biological Chemistry. 1979;254(3):987-995. doi:10.1016/s0021-9258(17)37901-2.
  • Haritos AA, Goodall GJ, Horecker BL. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proceedings of the National Academy of Sciences. 1984;81(4):1008-1011. doi:10.1073/pnas.81.4.1008.
  • Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-4239. doi:10.1182/blood-2003-11-4036.
  • Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha1. Expert Opinion on Biological Therapy. 2009;9(5):593-608. doi:10.1517/14712590902911412.
  • Tuthill CW, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Annals of the New York Academy of Sciences. 2010;1194:130-135. doi:10.1111/j.1749-6632.2010.05482.x.
  • Elizondo-Riojas MA, Chamow SM, Tuthill CW, Gorenstein DG, Volk DE. NMR structure of human thymosin alpha-1. Biochemical and Biophysical Research Communications. 2011;416(3-4):356-361. doi:10.1016/j.bbrc.2011.11.041.
  • Volk DE, Tuthill CW, Elizondo-Riojas MA, Gorenstein DG. NMR structural studies of thymosin alpha1 and beta-thymosins. Annals of the New York Academy of Sciences. 2012;1270:73-78. doi:10.1111/j.1749-6632.2012.06656.x.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.